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Abstract 
Background: Chronic hepatitis C virus (HCV) infection is a global health 
burden. Although HCV infection rarely contributes to morbidity during 
childhood, the majority of HCV infected children develop chronic HCV with a 
lifetime risk of liver disease. Little is known about the development of long-term 
liver disease and treatment effect in patients infected with HCV in childhood.  
Method: Retrospective review of patients infected with HCV in childhood 
enrolled in HCV Research UK. 
Results: 1049 patients were identified. The main routes of infection were 
intravenous drug use (53%); blood product exposure (24%); perinatal infection 
(11%). Liver disease developed in 32% of patients at a median of 33 years 
irrespective of mode of infection. Therefore, patients with perinatal exposure 
developed cirrhosis at an earlier age than the rest of the risk groups. Incidence 
of hepatocellular carcinoma (HCC) was 5%, liver transplant 4% and death 
occurred in 3%. Overall, 663 patients were treated (interferon/Peg interferon; 
55% or direct acting antivirals; 40%). Sustained virological response (SVR) 
was achieved in 406 (75%). There was higher mortality among patients without 
SVR vs SVR (5% vs 1%, p=0.003). Treatment was more effective in those 
without cirrhosis and disease progression was less (13%), compared to those 
patients with cirrhosis at the time of therapy (28%) p<0.001, who were more 
likely to develop HCC, require liver transplantation, or die. 
Conclusion: HCV infection in young people causes significant liver disease, 
which can now be prevented with antiviral therapy. Early treatment, especially 
before development of cirrhosis is essential. Detection of HCV should be aimed 
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at relevant risk groups and anti-viral therapy should be made available in 
childhood to prevent long-term liver disease and spread of HCV. 
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Lay summary 
Chronic HCV infection is a global health problem, which can now be treated 
with potent directly acting antiviral drugs. This study demonstrates (i) HCV 
infection in childhood causes serious liver disease in 32% of patients at a 
median of 33 years, irrespective of age, mode and route of infection (ii), the 
commonest routes of infection in those under 18 years of age in the UK are 
intravenous drug use (53%), via blood or blood products (24%) and via 
perinatal transmission (11%); (iii) disease outcome was better in patients 
treated before the development of advanced liver disease. Anti -viral therapy 
should be made available in childhood to prevent long-term liver disease and 
spread of HCV. 
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Introduction 
Chronic hepatitis C virus (HCV) infection is a global health burden with an 
estimated prevalence varying between 0.6%-10% dependent on geographical 
location and an estimated 71 million people worldwide with chronic  infection 
(1-3).  In Western Europe, the estimated prevalence is 1.5%-3.5%, but in the 
UK it is 0.5%. Chronic HCV is associated with increased morbidity and 
mortality and is a leading cause of end stage liver disease, cirrhosis and liver 
cancer worldwide (3-6). Although HCV infection rarely contributes to morbidity 
during childhood, the majority of HCV infected children develop chronic HCV 
with a lifetime risk of serious liver disease (7). Furthermore, some studies 
indicate that HCV affects childhood quality of life and behaviour, as cognitive 
function has been shown to be affected and families report  increased stress 
which affects family dynamics and wellbeing (7, 8).  
Several factors have been associated with accelerated disease progression but 
it is not clear whether or not infection in early life carries a different risk of 
progressive disease than infection in adulthood (9, 10). Since the mode of 
infection and genotype differs between countries and regions, knowledge of 
epidemiology at a local level is important in order to effectively plan prevention, 
surveillance, and prioritise treatment (11). Currently, there are little data on 
mode of infection, genotype and development of long term liver disease in 
patients infected with HCV in childhood in the UK.  
Currently, access to clinical trials of DAAs in childhood is limited which denies 
timely access to effective therapies for young infected children. HCV Research 
UK is a UK database and biobank which established a cohort of HCV infected 
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children and adults to address gaps in knowledge of epidemiology, treatment, 
disease progression, and prognosis (12, 13). 
The aim of this study was to describe the epidemiology and natural history of 
HCV in a UK cohort of patients who were infected during childhood. 
 
Patients and methods 
Retrospective, descriptive study of patients infected with HCV in childhood in 
the UK. 
 
The HCV Research UK database and Biobank 
HCV Research UK (HCV R UK) is a national, clinical, multicentre research 
database and biobank set up in 2012 to collect information about adults and 
children infected with HCV in the UK (12, 13). All highly populated areas of the 
UK are represented in the cohort and only patients who were in prison at time 
of clinic appointments or patients who were unable to give written informed 
consent were excluded from recruitment. More than 10,000 patients with past 
or current infection have been enrolled from 51 specialist adult and 7 paediatric 
HCV centres. Written informed consent was obtained at time of enrolment. For 
children under 16 years, this was supplied by parents or legal guardians. The 
HCV R UK database holds anonymised information including demographic 
data, risk factors for HCV infection including date of first exposure to risk, past 
and current alcohol intake, virology data, laboratory data,  biopsy and imaging 
results(13). The baseline data at enrolment of each participant is collected 
through a detailed, standardised questionnaire while follow-up data is collected 
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through assessment of medical notes. In addition, prospective clinical data on 
risk behaviours, physical characteristics, HCV virology, comorbidities, liver 
disease status, treatment, and mortality are collected biennially for all patients 
in the cohort.  
Diagnosis of cirrhosis was made at the discretion of the local physician by 
histology, imaging studies, serum markers or clinical diagnosis with 
accompanying clinical signs (ascites, portal hypertension, and/or variceal 
bleed).  
 
Patients 
Clinical and epidemiological data from patients enrolled in the HCV R UK 
clinical database and biobank was requested in October 2016 and the data 
updated in March 2017. Patients were included if age at first infection was 
estimated (based on first exposure to risk) to be between 0-18 years or if age 
between 0-18 years was recorded at the time of first positive HCV test, the time 
of first attendance or at the time of consent.  
 
Statistical analysis 
Statistical analyses were performed using STATA 13 (StataCorp LP, Texas). 
Clinical characteristics were analysed in a descriptive way and reported as 
mean ± standard deviation (SD) or median and range where assumptions of 
normal distribution were not met. For pairwise comparison, chi square test was 
used for binary outcome variables and Fisher exact test was used for small 
samples.  
9 
  
The unpaired t-test and multivariate logistic regression with indicator variable 
was used for continuous numerical outcome variables and Wilcoxon rank-sum 
test was used for non-normally distributed data.  
Statistical significance was defined as p<0.05. 
 
Results 
Demographic data 
In total, 1086 patients infected with HCV in childhood were identified from the 
HCV R UK database of whom 37 patients were excluded due to discrepancies 
between date of birth, date of infection and possible infection route leaving 
1049 patients for data analysis. Estimated time of first infection between 0 and 
18 years was given in 984/1049 (94%) of patients, while the remaining 65 
patients were included based on age <18yrs at their first positive HCV test 
(n=64) or their age at consent <18yrs (n=1). Baseline characteristics of the 
cohort are shown in table 1. 
HCV genotypes, tested in 938 patients (89%), were G1: 531 (57%); G2: 50 
(5%); G3: 328 (35%), G4: 27 (3%), G5: 1 (0.1%) and mixed type: 1 (0.1%).  
Forty-four (4%) patients were co-infected with HIV of whom 41 (93%) were 
treated with antiretrovirals; 363 (35%) had a history of heavy alcohol use – 
301/759 (40%) males and 62/287 (22%) females, p<0.001. Spontaneous 
clearance of infection was seen in 3% (36/1049), of whom 26 (72%) were 
males.  
 
Route of infection 
10 
  
Patient characteristics by mode of infection are shown in table 2. The most 
prevalent route of infection was intravenous drug use (IVD group): 560 (53%), 
followed by receipt of blood products (blood group): 251 (24%), including 85 
with coagulation bleeding disorders; perinatal exposure (perinatal group): 119 
(11%) and unknown or other route of infection (unknown group): 119 (11%). 
There were less male patients in the perinatal group (35%) compared to the 
IVD blood and other infection route groups (78%, 77% and 73% respectively, 
p<0.001). The genotype distribution shows fewer genotype 3 infections in the 
blood group (18%) compared to the other 3 groups (35%) (p<0.001). 
Median age at first infection was 16yrs (range 10-18) in the IVD group, 11yrs 
(range 0-17yrs) in the blood group and at birth (0yrs) in the perinatal group 
(figure 1). The gap between infection and diagnosis was a median 19 to 24yrs 
in the IVD group, blood group and unknown risk group and 2yrs in the perinatal 
group.  
 
Development of liver disease 
In total, 334/1049 (32%) of patients had a diagnosis of cirrhosis at the time of 
data analysis. Cirrhosis was diagnosed by liver biopsy (110, 33%), imaging 
studies including transient elastography (85, 25%), endoscopy or clinical signs 
of cirrhosis (101, 30%), serum markers (7, 2%) and unknown/missing (31, 9%). 
By multivariate regression analysis, significant risk factors for the development 
of cirrhosis were male gender (p=0.003, OR 1.6 [95%CI 1.2-2.2]) and heavy 
alcohol use (p<0.001, OR 1.6 [95%CI 1.2-2.8]) while HIV co-infection was not 
significant (p=0.88, OR 0.95 [95%CI -0.2-0.5]). The time to cirrhosis and age at 
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development of liver disease between the different risk groups is presented in 
figure 2 and shows that the rate of liver disease progression appears to be 
similar across all patient groups. 
The median time to develop cirrhosis was 33yrs (range 12-53yrs) which was 
estimated in 281/334 (84%) patients. There was no significant difference 
between any of the groups (IVD group: 33yrs; blood group: 32yrs; perinatal 
group 36yrs; unknown group: 36yrs), (p=0.76). Thus, patients with perinatal 
infection developed cirrhosis earlier at a median age of 36yrs (range 17-53yrs) 
compared to 48yrs (range 33-68yrs), 46yrs (range 12-61yrs), and 51.5yrs 
(range 12-65yrs) in the IVD, blood, and unknown groups, respectively 
(p<0.001).  
There were less patients with cirrhosis in the perinatal group (8%, 10/119) 
compared to the IVD, blood and unknown groups (37%, 205/560; 32%, 79/250; 
34%, 40/119) (p<0.001). However, 101 (85%) of patients with perinatal 
infection were younger than 33yrs of age at the time of data analysis and so 
may not have had time to develop cirrhosis, whilst 7 of the 18 (38%) above the 
age of 33yrs had developed cirrhosis, suggesting a similar pattern of 
development of cirrhosis irrespective of infection route. Cirrhosis developed in 
the perinatal group despite the low prevalence of associated risk factors (male 
gender, heavy alcohol use) compared to the IVD group (table 2). 
HCC was diagnosed in 55/1049 (5%) of the patients. Of these 55 patients 
38/55 (70%) were from the IVD group, 11/55 (20%) in the blood product group, 
and 6/55 (10%) of the patients in the unknown group. 44 of the 55 patients with 
HCC (80%) had cirrhosis prior to the diagnosis of HCC. There was no 
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difference in heavy alcohol use between patients with (23/44, 52%) or without 
cirrhosis (6/11, 55%), p=0.9 prior to diagnosis of HCC. Overall, median time to 
development of HCC was 39yrs (range 23-53 years) while median age at 
diagnosis of HCC was 55yrs (range 37-68yrs), figure 3. 
46 (4%) of patients had received a liver transplant (LTx). Of these, 33 were 
cirrhotic and 17 had HCC at the time of transplant. Median time to LTx from 
first infection was 34yrs (range 16-50yrs) while median age at time of LTx was 
49yrs (range 27-66yrs), figure 4. There was no significant effect of mode of 
transmission (p=0.90; p=0.18) respectively). There was no difference between 
those who required LTx and those who did not with regard to HIV co-infection 
(2/47 (4%) vs. 42/1002 (4%), p=0.2) or history of heavy alcohol use (21/47 
(44%) vs. 342/1002 (34%), p=0.1). Renal failure was reported more frequently 
in patients who had LTx (4/47 (9%) vs. 7/1002 (0.7%), p=0.001). 
The overall mortality in the cohort was 3% (28/1049). In multivariate analysis 
the presence of cirrhosis (p<0.001, OR 6.2 [95%CI 2.6-14.7]) was the only 
significant risk factor. Heavy alcohol use (p=0.3, OR 1.5 [95%CI 0.7-3.3]), HCC 
(p=0.8, OR 1.2 [95%CI 0.4-3.9]), gender (p=0.8, OR 1.6 [95%CI 0.5-3.3]) and 
LTx (p=0.9, OR 1.0 [95%CI 0.3-3.7]) were not associated with mortality. 
 
Treatment 
In total 663 (63%) patients in the cohort had received treatment, 133 and 46 of 
whom received 2 and 3 separate treatment regimens, respectively. Treatment 
outcome was missing for 122 individuals. Of the 541 patients whose treatment 
outcome was known, for 292 (54%) the last treatment was an interferon (INF) 
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based treatment regimen + ribavirin (RBV); only 6 patients (1%) had INF 
alone;95 (18%) had  INF in combination with direct acting antivirals (DAAs).  
119 (22%) received DAAs alone. In 29 (5%) patients, the treatment regimen 
was unknown, mostly because they had taken part in clinical trials. Overall, 
sustained virological response (SVR) was achieved in 406 (75%) patients while 
135 (25%) patients were non-responders or responder-relapsers. Treatment 
outcomes stratified by the last regimen received and liver disease status are 
shown in table 3. There was no difference in the overall SVR rates between 
non-cirrhotic and cirrhotic patients (265/360 [74%] vs 111/142 [78%], p=0.29), 
although this is confounded by the fact that 314/360 (87%) of the former group 
received an INF-containing regimen, whilst 67/142 (47%) of the latter group 
received all DAA regimens. The apparently higher SVR rate in cirrhotic patients 
treated with an interferon-based regimen (32/46, 70%) as compared to non-
cirrhotic patients (162/238, 68%) is probably because in the former group the 
predominant genotype was GT3 (28/46, 61%), who generally have a better 
response to IFN therapies,  whereas in the latter group it was GT1 (115/238, 
48%), with only 97 (40%) GT3 infections.  
 
Progression of liver disease 
502 patients underwent treatment with complete data (i.e. the treatment 
regimen, outcome and liver disease status were known 142 with cirrhosis and 
360 patients without. Progression of liver disease according to treatment 
outcome in patients treated with and without cirrhosis is shown in table 4.  
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Disease progression occurred in 87/502 (17%); 47/360 (13%) events were 
recorded in those without cirrhosis, compared to 40/142 (28%) in patients with 
cirrhosis (p<0.001). Progression to cirrhosis was seen in 24/265 (9%) patients, 
who achieved SVR, compared to 15/95 (16%) who failed to achieve SVR (p = 
0.07). Progression to HCC, liver transplant or death was seen almost 
exclusively in those patients who were cirrhotic at treatment onset. Although 
HCC developed in 16 cirrhotic patients post-SVR, in 12 of these patients, the 
HCC was diagnosed in the same year that SVR was recorded. It is highly 
likely, therefore, that many, if not all of these tumours did not arise de novo 
post SVR in a non-infected liver, but were present during the period of therapy 
and follow-up to assessment of treatment outcome.  
The median length of follow-up for the cirrhotic patients, without further liver 
disease at time of data analysis was 3 years for those with SVR (range 0-20 
years) and 3 years (range 1-13 years) for non-SVR patients. For the non-
cirrhotic patients the follow-up time was 5 years (range 1-24 years) for SVR 
patients and 6 years (range 1-22 years) for non-SVR patients. 
 
Significantly more patients with SVR treated with cirrhosis compared to 
patients treated before diagnosis of cirrhosis progressed to HCC (16 [14%] vs. 
2 [1%], p<0.001), or required LTx (7 [6%] vs. 3 [1%], p=0.005) or died (5 [4%] 
vs. 0 [0%], p=0.001 (table 4). Furthermore, mortality amongst cirrhotic patients 
who achieved SVR (5/111, 4%) was significantly less than for those who did 
not achieve SVR (7/31, 23%, p = 0.004).  
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Discussion 
This is the first study to describe the epidemiological characteristics and 
development of long term liver disease in a UK cohort of patients infected with 
HCV in childhood. The main route of infection was IV drug use in adolescents 
in the UK. Serious long term liver disease developed in one third of the patients 
and treatment was more effective in those who were treated before cirrhosis 
developed, as those treated with cirrhosis were more likely to develop HCC, 
require liver transplantation, or die. 
Studies of the development of liver disease in adult patients with chronic HCV 
prior to treatment have found that alcohol intake and severity of portal fibrosis 
are correlated with future disease progression and development of cancer (14). 
There are few studies describing disease progression in adulthood in patients 
who were infected with HCV during childhood. Many studies are in 
heterogeneous populations with insufficient long term follow-up to provide clear 
outcomes.  (14-17). Previous studies have reported that HCV infection in 
children differs from adults in some ways such as modes of transmission, rates 
of clearance, progression of fibrosis, and the duration of potential chronic 
infection when acquired at birth (18, 19). A risk of the development of hepatic 
fibrosis whilst in childhood of less than 2% has been reported , but this is much 
higher in patients with longer follow-up and duration of infection, indicating 
disease progression is more likely 10 years after the onset of infection (20-23). 
Other paediatric studies have demonstrated that the degree of hepatic fibrosis 
correlates with age and duration of infection and suggest that progression 
occurs at a slower pace in young children compared to those infected late in 
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life (16, 24-27). Disease may progress more rapidly in older patients due to the 
presence of  multiple additional risk factors such as alcohol consumption and 
co-infection with HIV, and therefore it is important to distinguish between 
disease development in those infected as neonates and young people versus 
disease development in young adults (18, 28-30). 
The proportion of HCV-infected children who may develop serious long-term 
liver disease is not clear from the current literature. In this study 33% of 
patients infected with HCV in childhood developed long term liver disease 
including cirrhosis, HCC or a requirement for LTx. A critical finding in our 
analysis was that the long-term development of progressive liver disease is 
independent of the age or route of acquisition, with a median time to diagnosis 
of 32-36 years. Other studies have suggested that vertically infected children 
may develop liver disease more frequently than children infected by blood 
products (31-33). However, most of these studies do not have data beyond 
10yrs of follow-up of children infected with HCV and are likely to underestimate 
the proportion of HCV-infected children who will develop long-term liver 
disease. Cirrhosis was less frequent in perinatally infected patients compared 
to the other risk groups in our cohort. However, perinatally infected patients 
older than 33 years in our cohort had the same frequency of cirrhosis as the 
other risk groups, even though heavy alcohol use was much less frequent in 
this subgroup. 
The rate of disease progression is influenced by a variety of host, viral, and 
environmental factors, most notably alcohol abuse and coinfection with HBV 
and HIV (2, 34). Such associations were not evident in our cohort, most likely 
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because of the relatively low frequency of these risk factors in those children 
infected at an early age.  
There was more than a 20 year delay between suspected time of infection and 
diagnosis of HCV in this chort, except in the perinatally infected patients, 
probably because  of lack of HCV testing in  relevant paediatric risk groups (9). 
As all blood donors are now screened for all blood borne viruses, vertical 
transmission of HCV via mother-to-child transmission is now reported to be the 
leading cause of paediatric infection globally while risk factors for HCV infection 
in adults include IVD use, blood transfusion before 1992 and HIV-infection (35-
38).  
In this cohort, in contrast to other paediatric studies, more than half of the 
infected patients reported IV drug use in adolescence as the main route of 
infection, followed by blood product exposure, while vertical transmission only 
accounted for 11% of the cases (39, 40). These data reflect the long term 
follow up of this cohort infected with HCV prior to screening of blood products 
and modern management of IV drug abuse (41, 42). These data may be an 
under-estimate of the actual number of UK children infected with HCV as it is 
likely that many are not identified and hence are not receiving appropriate 
treatment and counselling. Healthcare workers at primary and secondary 
healthcare levels should encourage testing of relevant risk groups, such as 
young adolescents who participate in IV drug use and the children of such 
individuals.  
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75% of the treated patients in this cohort achieved SVR. Life-threatening 
complications of end stage liver disease were much less frequent in patients 
treated before they became cirrhotic (see Table 4) as reported previously in the 
literature (43, 44).  
We have not attempted a more detailed interpretation of the treatment data in 
this cohort since the data were collected during a period when there were rapid 
changes in HCV treatment regimens,and there are a number of possible 
confounders. For instance, many of the patients treated with DAAs will be 
those who had failed earlier treatment regimens, and will thus have been a 
“difficult-to-treat” group, with potentially more severe liver disease at time of 
initiation of treatment. Nevertheless, our data provide a clear indication of the 
need to start treatment as early as possible before the development of 
established liver disease. We have confirmed previous reports that 
achievement of SVR in patients with cirrhosis reduces, but does not eliminate, 
the risk of HCC development. (32, 33, 45).  
Some limitations should be taken into account when interpreting the results. 
The duration of infection was estimated on the assumption that patients were 
infected at time of first exposure to risk. For the IVD group, this is a 
simplification since it is possible that actual infection occurred sometime later in 
life. Calculations based on the risk of infection in IVD users suggests that 
around 50% of all IVD users who acquire HCV infection do so within 3 years of 
onset of injecting behaviour (46). Thus, our quoted estimate of time to cirrhosis 
for this group may be a slight overestimate. 
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Treatment data from this cohort reflects historical practice as INF based 
treatment regimens are no longer recommended in adult guidelines and DAAs 
are the preferred treatment with high SVR rates and few side-effects. However, 
only two DAAS are licensed in children over 12 years of age (sofosbuvir with 
ribavirin and sofosbuvir/ledipasvir) . Although clinical trials of DAA’s are 
ongoing in children under 12 years, there will be a delay until they are licensed 
(11). 
It is likely that we have not enrolled all children with HCV infection in the UK 
and so  there may be selection bias in recruitment of patients who attended 
specialist clinics, who may have had more severe liver disease (47). However, 
we believe the cohort is representative of patients with HCV infection attending 
specialist treatment centres and therefore an assessment of the long-term 
outcome of HCV infection in this population. The strengths and limitations of 
the HCV Research UK cohort are described in more detail elsewhere (13). 
In conclusion, HCV infection in childhood causes serious long-term liver 
disease which is an important and ongoing problem in in the UK which can now 
be prevented with antiviral therapy. Early treatment, especially before 
development of cirrhosis, significantly decreases morbidity and mortality 
associated with HCV infection. We recommend that healthcare workers are 
aware of the prevalence of HCV in childhood, particularly in young 
adolescents, and that testing according to NICE guidelines are implemented 
and treatment is made available. Pharmacological treatment of chronic HCV in 
childhood should be provided to children by health authorities based on the 
present evidence of increased risk of serious liver disease in adulthood.  
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Tables 
 
Table 1 Patient characteristics of 1049 patients enrolled in the HCV Research UK project between 
March 2012 and October 2016. 
Demographic variable Result n 
Male 759 (72.3) 10461 
Age at infection, median (range) 15 (0-18) 1049 
Age at first positive HCV test, median (range) 33 (0-65) 1049 
Current age, median (range) 50 (3-77) 1049 
Ethnicity   
White 945 (90.9) 10402 
Asian 52 (5.0) 10402 
African 12 (1.2) 10402 
Arabic 8 (0.8) 10402 
Other 23 (2.2) 10402 
Infection route   
Intravenous drug use 560 (53.4) 1049 
Transfusion of blood/blood products 251 (23.9) 1049 
Vertical transmission 119 (11.4) 1049 
Other or unknown transmission route3 119 (11.4) 1049 
Genotype   
1 531 (56.6) 9384 
2 50 (5.3) 9384 
3 328 (35) 9384 
4 27 (2.9) 9384 
5 1 (0.1) 9384 
Mixed 1 (0.1) 9384 
Risk factor for infection   
Coagulation bleeding disorder5 85 (8.2) 10325 
Co-factors for disease progression   
HIV co-infection 44 (4.4) 9986 
History of heavy alcohol use 363 (35.3) 10297 
Data in the table are presented as n (%), unless otherwise specified. HCV: Hepatitis C virus, HIV: Human 
immunodeficiency virus 
1Missing: 3, 2Missing: 9, 3Including tattoos, dental work, born abroad, surgery, and unknown, 4Missing/unknown: 111, 
5Haemophilia, idiopathic thrombocytopenic purpura, Von Willebrands, thalassemia, missing: 17, 6Missing/not tested: 
51, 7Missing: 20 
 
25 
  
Table 2 Patient characteristics and development of liver disease in 1049 patients diagnosed with 
hepatitis C in childhood by mode of infection. 
Demographic variable Infection route 
 
Perinatal group 
(n=119) 
Blood group 
(n=251) 
IV group 
(n=560)1 
Unknown group 
(n=119) 
Male 42 (35) 194 (77) 434 (78) 87 (73) 
Age at first infection, years, median (range) 0 (0-1) 11 (0-17) 16 (10-18)  15 (0-18) 
Age at first positive HCV test, years, median (range) 2 (0-53)2 29 (0-64) 38 (12-65) 37 (3-65) 
Years between first infection and diagnosis, years, 
median (range) 
2 (0-53) 19 (0-52) 22 (0-51) 24 (0-50) 
Current age years, median (range) 14 (3-55) 48 (21-73) 52 (21-77) 52 (10-72) 
Follow-up time, years, median (range) 13 (3-55) 36 (8-59) 37 (5-61) 37 (4-57) 
Genotype      
1 59 (50) 159 (64) 257 (46) 56 (47) 
2 1 (1) 9 (4) 34 (6) 6 (5) 
3 42 (35) 46 (18) 198 (35) 42 (35) 
4 and 5 6 (5) 9 (4) 10 (2) 3 (3) 
Mixed type - - - 1 (1) 
Unknown 11 (9) 28 (10) 61 (11) 11 (9) 
Risk factors for disease progression     
History of heavy alcohol use 2 (2) 39 (16) 279 (50) 43 (36) 
IV drug use within the last 6 months - - 45 (8) 12 (0.8) 
Development of liver disease     
Cirrhosis 10 (8) 79 (32) 205 (37) 40 (34) 
Age at cirrhosis, years, median (range) 36 (17-53) 46 (23-61) 48 (33-68) 52 (12-65) 
Years between first infection to cirrhosis 
diagnosis, years, median (range) 
36 (17-53) 32 (12-53) 33 (17-51) 36 (1-50) 
Hepatocellular carcinoma - 11 (4) 38 (7) 6 (5) 
Age at time of hepatocellular carcinoma, years, 
median (range) 
- 55 (37-63) 56 (48-68) 54 (52-54 
Years from first infection to hepatocellular 
carcinoma, years, median (range) 
- 42 (23-53) 40 (32-51) 38 (35-39) 
Liver transplant4 - 13 (5) 28 (5) 53 (4) 
Age at time of liver transplant, years, median 
(range) 
- 46 (27-63) 50 (36-66) 51 (4-54) 
Years from first infection to liver transplant, years, 
median (range) 
- 37 (16-49) 33 (20-50) 36 (28-39) 
Death - 6 (2) 19 (3) 7 (6) 
Data in the table are presented as n (%), unless otherwise specified. HCV: Hepatitis C virus, HIV: Human 
immunodeficiency virus. 
1One patient was registered in the database with other route of infection (born abroad) and no other risk factor for 
infection but having IV drug use within the last 6 months.  
2One patient born in Lithuania was registered in the database with an age of 53 at time of first positive HCV test 
corresponding to the same year the patient was enrolled in HCV Research UK. 
3Year 2017 was used to calculate current age when data retrieval was conducted. 
4One patient has been excluded from transplant data analysis due to transplant on the basis of biliary atresia before 
the diagnosis of HCV. 
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Table 3. Treatment outcome according to disease status at onset of therapy and treatment regimen in 
patients infected with HCV in childhood in whom treatment outcome is known. 
Treatment 
regimen 
Non-cirrhotic1  Cirrhotic2 Cirrhosis status unknown3 
N SVR Non-SVR N SVR Non-SVR N SVR Non-SVR 
INF (n=6) 
4  
(67%) 
2 
(50%) 
2  
(50%) 
2 
(33%) 
2 
(100%) 
- - - - 
INF+RBV 
(n=292) 
238 
(81%) 
162 
(68%) 
76 
(32%) 
46 
(16%) 
32 
(70%) 
14 
(30%) 
8  
(3%) 
6  
(75%) 
2  
(25%) 
INF+DAA  
(n=95) 
72 
(76%) 
61 
(85%) 
11 
(15%) 
19 
(20%) 
14 
(74%) 
5 (26%) 
4  
(6%) 
3  
(75%) 
1  
(25%) 
DAA 
(n=119) 
25 
(21%) 
22 
(88%) 
3  
(12%) 
67 
(56%) 
56 
(84%) 
11 
(16%) 
27  
(23%) 
21 
(78%) 
6  
(22%) 
Unknown 
(n=29) 
21 
(72%) 
18 
(86%) 
3  
(14%) 
8  
(28%) 
7  
(88%) 
1  
(12%) 
0 0 0 
Total 
(n=541) 
360 
(67%) 
265 
(74%) 
95 
(26%) 
142 
(26%) 
111 
(78%) 
31 
(22%) 
39  
(7%) 
30 
(77%) 
9  
(23%) 
Data is presented as n (%). DAA: Direct acting antiviral; INF: Interferon based treatment regimen; RBV: 
Ribavirin; SVR: Sustained virological response. 
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Table 4. Disease progression according to disease status at onset of therapy and treatment outcome for 
patients infected with HCV in childhood. 
Event 
 Non-cirrhotic Cirrhotic 
TOTAL 
(n=502) 
SVR 
(n=265) 
Non-SVR 
(n=95) 
SVR 
(n=111) 
Non-SVR 
(n=31) 
Cirrhosis 391 (11%) 24 (9%) 15 (16%) NA NA 
HCC 23 (5%) 22 (1%) 1 (1%) 163 (14%) 4 (13%) 
LTx 11 (2%) 3 (1%) 0 7 (6%) 1 (3%) 
Death 14 (3%) 0 24 (2%) 55 (5%) 76 (23%) 
Data is presented as n (%). HCC: Hepatocellular carcinoma; LTx: Liver transplantation; SVR: Sustained virological 
response. 
1This outcome only applies to patients who were non-cirrhotic before therapy, the denominator is 360. 
2One patient also had a liver transplant. 
3Six patients also had a liver transplant. 
4No record of cause of death. 
5One patient had a liver transplant + HCC before death. Two patients had other cancers, one patient with no 
record of cause of death. 
6One patient had a liver transplant and one patient died with HCC, one patient with no record of cause of death. 
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Figure legends 
Fig. 1. Patient age at infection by risk group in patients infected with HCV in childhood. 
 
Fig. 2. Time between first infection and diagnosis of cirrhosis and real age in patients 
infected with HCV in childhood. HCC: hepatocellular carcinoma; LTx: liver transplantation. 
 
Fig. 3. Time between first infection and diagnosis of hepatocellular carcinoma and real 
age in patients infected with HCV in childhood. HCC: hepatocellular carcinoma; LTx: liver 
transplantation. 
 
Fig. 4. Time between first infection and time of liver transplantation and real age in 
patients infected with HCV in childhood. HCC: hepatocellular carcinoma; LTx: liver 
transplantation. 
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